Sign up
Log in
George
China-Coronavirus/Vaccine Trials
Beijing, China - Recent (CCTV - No access Chinese mainland)
1. Various of pictures of COVID-19 vaccine for clinical trials
2. Various of researchers working in laboratory
3. SOUNDBITE (Chinese) Wang Hui, president, National Vaccine and Serum Institute (partially overlaid with shot 4):
"It usually takes several years for the research and development of a vaccine. But we have been working on shifts round the clock, which shortens the time span. This also demonstrates our Chinese strength and speed."
++SHOT OVERLAYING SOUNDBITE++
4. Various of researchers
++SHOT OVERLAYING SOUNDBITE++
5. Various of researchers working
6. Picture of COVID-19 vaccine for clinical trials
7. Sign reading "Inactivated COVID-19 Vaccine Manufacturing Campus"
8. SOUNDBITE (Chinese) Dong Jianchun, head, engineering support department, National Vaccine and Serum Institute (starting with shot 7/ending with shot 9):
"From the site selection to the construction completion, it took 78 days to build the workshop, while the real construction period was only about 60 days. This is the first workshop of high-level bio-safety protection for human use in China."
9. Various of researchers putting on protective gear
10. Experiment in progress
11. SOUNDBITE (Chinese) Zhu Jingjin, head, China National Biotec Group (starting with shot 10):
"After the workshop comes into being, the vaccine produced from it could serve special groups of people, like medical workers, diplomats, Belt and Road construction workers and returned students abroad according to law with the approval of relevant state departments."
12. Various of researchers operating instruments
China's fourth COVID-19 vaccine went into clinical trials in Henan Province on Tuesday.
The vaccine is developed by the National Vaccine and Serum Institute under the China National Biotec Group (CNBG).
This is the second inactivated COVID-19 vaccine the CNBG has developed and the Chinese National Medical Products Administration has approved of clinical trials. The country's first inactivated COVID-19 vaccine entered the second-phase clinical trial on Friday.
Since the novel coronavirus outbreak, the CNBG has allotted 1 billion yuan (about 141.29 million U.S. dollars) to develop COVID-19 vaccines in three of its research institutes along two technical routes.
"It usually takes several years for the research and development of a vaccine. But we have been working on shifts round the clock, which shortens the time span. This also demonstrates our Chinese strength and speed," said Wang Hui, president of the National Vaccine and Serum Institute.
Wang said that the research team has conquered a series of key technologies in the vaccine's production and quality control, and has made three clinical samples of high, moderate and low doses. The vaccine will not be able to go to the market until the third phases of clinical trials is completed.
The CNBG has built in Beijing the largest COVID-19 vaccine workshop in the world, with a designed capacity to produce 100 million doses after annually, able to meet the demand for large-scale emergency use and routine vaccination.
"From the site selection to the construction completion, it took 78 days to build the workshop, while the real construction period was only about 60 days. This is the first workshop of high-level bio-safety protection for human use in China," said Dong Jianchun, head of the engineering support department of the National Vaccine and Serum Institute.
"After the workshop comes into being, the vaccine produced from it could serve special groups of people, like medical workers, diplomats, Belt and Road construction workers and returned students abroad according to law with the approval of relevant state departments," said Zhu Jingjin, head of the CNBG.
China-Coronavirus/Vaccine Trials
Dateline : Recent
Location : China
Duration : 1'41
Beijing, China - Recent (CCTV - No access Chinese mainland)
1. Various of pictures of COVID-19 vaccine for clinical trials
2. Various of researchers working in laboratory
3. SOUNDBITE (Chinese) Wang Hui, president, National Vaccine and Serum Institute (partially overlaid with shot 4):
"It usually takes several years for the research and development of a vaccine. But we have been working on shifts round the clock, which shortens the time span. This also demonstrates our Chinese strength and speed."
++SHOT OVERLAYING SOUNDBITE++
4. Various of researchers
++SHOT OVERLAYING SOUNDBITE++
5. Various of researchers working
6. Picture of COVID-19 vaccine for clinical trials
7. Sign reading "Inactivated COVID-19 Vaccine Manufacturing Campus"
8. SOUNDBITE (Chinese) Dong Jianchun, head, engineering support department, National Vaccine and Serum Institute (starting with shot 7/ending with shot 9):
"From the site selection to the construction completion, it took 78 days to build the workshop, while the real construction period was only about 60 days. This is the first workshop of high-level bio-safety protection for human use in China."
9. Various of researchers putting on protective gear
10. Experiment in progress
11. SOUNDBITE (Chinese) Zhu Jingjin, head, China National Biotec Group (starting with shot 10):
"After the workshop comes into being, the vaccine produced from it could serve special groups of people, like medical workers, diplomats, Belt and Road construction workers and returned students abroad according to law with the approval of relevant state departments."
12. Various of researchers operating instruments
China's fourth COVID-19 vaccine went into clinical trials in Henan Province on Tuesday.
The vaccine is developed by the National Vaccine and Serum Institute under the China National Biotec Group (CNBG).
This is the second inactivated COVID-19 vaccine the CNBG has developed and the Chinese National Medical Products Administration has approved of clinical trials. The country's first inactivated COVID-19 vaccine entered the second-phase clinical trial on Friday.
Since the novel coronavirus outbreak, the CNBG has allotted 1 billion yuan (about 141.29 million U.S. dollars) to develop COVID-19 vaccines in three of its research institutes along two technical routes.
"It usually takes several years for the research and development of a vaccine. But we have been working on shifts round the clock, which shortens the time span. This also demonstrates our Chinese strength and speed," said Wang Hui, president of the National Vaccine and Serum Institute.
Wang said that the research team has conquered a series of key technologies in the vaccine's production and quality control, and has made three clinical samples of high, moderate and low doses. The vaccine will not be able to go to the market until the third phases of clinical trials is completed.
The CNBG has built in Beijing the largest COVID-19 vaccine workshop in the world, with a designed capacity to produce 100 million doses after annually, able to meet the demand for large-scale emergency use and routine vaccination.
"From the site selection to the construction completion, it took 78 days to build the workshop, while the real construction period was only about 60 days. This is the first workshop of high-level bio-safety protection for human use in China," said Dong Jianchun, head of the engineering support department of the National Vaccine and Serum Institute.
"After the workshop comes into being, the vaccine produced from it could serve special groups of people, like medical workers, diplomats, Belt and Road construction workers and returned students abroad according to law with the approval of relevant state departments," said Zhu Jingjin, head of the CNBG.
ID : 8141634
Published : 2020-04-29 10:26
Last Modified : 2020-04-30 16:55:00
Source : China Central Television (CCTV)
Restrictions : No access Chinese mainland
More
